- Home
- INSW vs VCEL Comparison
INSW vs VCEL Comparison
Compare INSW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INSW | VCEL |
|---|---|---|
| Founded | 1999 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 1.7B |
| IPO Year | 2016 | 1996 |
Fundamental Metrics
Financial Performance| Metric | INSW | VCEL |
|---|---|---|
| Price | $71.42 | $32.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $69.33 | $58.50 |
| AVG Volume (30 Days) | ★ 650.6K | 487.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.32% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 6.23 | 0.32 |
| Revenue | ★ $843,302,000.00 | $276,259,000.00 |
| Revenue This Year | $2.80 | $19.09 |
| Revenue Next Year | N/A | $17.96 |
| P/E Ratio | ★ $11.16 | $100.88 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $27.20 | $29.24 |
| 52 Week High | $78.51 | $48.75 |
Technical Indicators
Market Signals| Indicator | INSW | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 38.81 |
| Support Level | $36.90 | $31.34 |
| Resistance Level | $78.51 | $38.15 |
| Average True Range (ATR) | 2.92 | 1.21 |
| MACD | -0.90 | -0.15 |
| Stochastic Oscillator | 45.80 | 32.46 |
Price Performance
Historical ComparisonAbout INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.